期刊
PEDIATRIC BLOOD & CANCER
卷 62, 期 7, 页码 1144-1148出版社
WILEY
DOI: 10.1002/pbc.25462
关键词
BCP-ALL; blinatumomab; CD19; childhood leukemia; pre-BCR
资金
- Cancer Research UK [12788] Funding Source: Medline
- Cancer Research UK [12788] Funding Source: researchfish
Over the last 20-30 years CD19 has gained attention as a potential target in the therapy of B-cell malignancies. In particular, targeting CD19 with the bispecific T-cell engager (BiTE) antibody Blinatumomab and T-cells modified by chimeric antigen receptors (CAR) has shown promising efficacy in early phase clinical trials for adults and children with precursor B-cell ALL (BCP-ALL). This review will discuss the rationale behind targeting CD19 in BCP-ALL and its potential importance in BCP-ALL signaling pathways. Pediatr Blood Cancer 2015;62:1144-1148. (c) 2015 Wiley Periodicals, Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据